The significant improvement observed in NYHA functional class with S/V therapy, previously detailed, was mirrored in patients with and without CKD by significantly lower levels of NT-proBNP (p < 0.001 for both groups) and improved LVEF (9.1 ± 11% vs. 8.1 ± 11%, p = 0.678) at the end of follow up, suggesting a positive remodeling benefit of the drug [18]. Here, NPPB is linked to chronic kidney disease.